Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized, double-blind, placebo-controlled study of satralizumab in neuromyelitis optica and neuromyelitis optica spectrum disorder
2013-003752-21Phase 3Unknown
- Sponsor
- Roche
- Start
- Oct 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in neuromyelitis optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) comparing Satralizumab plus baseline treatment with Placebo plus baseline treatment (2 arms). Status: unknown.
02
Drugs
satralizumab
03
Conditions
neuromyelitis optica (NMO)Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2013-003752-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003752-21.